Pregabalin Treatment for RDEB Pain and Itch
A Double-blind, Randomized, Cross-over, Feasibility Trial of Pregabalin for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-associated Neuropathic Pain and Itch
Sponsor: Epidemolysis Bullosa Research Partnership
A PHASE3 clinical study on Epidermolysis Bullosa and Itch, this trial is completed. The trial is conducted by Epidemolysis Bullosa Research Partnership and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Nov 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Epidemolysis Bullosa Research Partnership
- The Hospital for Sick Children
For direct contact, visit the study record on ClinicalTrials.gov .